Plain-English translation of NCT06462586 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a research study testing whether , a new medication, can help people during acute manic episodes related to bipolar I disorder. In the study, some participants will receive the medication while others receive a placebo (a dummy pill), and researchers will measure how well it works and how safe it is. This is a Phase 3 trial, meaning the medication has already shown promise in earlier testing and is now being studied in a larger group of people.
Manic episodes can be severe and frightening, often requiring hospitalization. While treatments exist, doctors are always looking for new options that might work better or have fewer side effects. This study is testing whether this medication could offer another choice for people in crisis.
You likely qualify if…
You likely don't qualify if…
You will be in the hospital during the study. First, you'll go through a screening period of up to one week to confirm you qualify. Then you'll be randomly assigned to receive either the medication or placebo once daily for three weeks—neither you nor the research team will know which one you're getting. After the three-week treatment period, you'll return for a follow-up safety visit one week later. Throughout the study, the research team will monitor your symptoms and overall health.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States